Pharma 2100

AN ANALYSIS OF FUNDING ALLOCATION IN GLOBAL PHARMACEUTICAL COMPANIES


Is our country focused more on fixing our problems or on preventing our problems? 


Inspired by the way the U.S. healthcare is portrayed in Matthew Heineman and Susan Froemke’s documentary “Escape Fire,” the purpose of this study is to analyze the global pharmaceutical industry and gauge where the emphasis on funding lies between therapeutic and preventive methods in our health. The intended audience is a mix of governmental leaders, related R & D start-ups, and curious global citizens who care about the trajectory of their healthcare system.

The following data is based on a small sampling of the currently(2017) active pharmaceutical companies around the world. About a 10% random sample were taken from each bucket of different sized companies (measured by the number of employees). This data was obtained in 2017 through the Orbis Database, the World Bank Data, and the Bloomberg Global Health Index.

Pharma 2100 diagram

Process


Since there is no existing listed category to list whether a company is focused around more therapeutic care or preventive, I have devised an initial method of parsing the data. Based on the companies' trade and product descriptions, I ran an algorithm to select and count certain keywords that are associated with either preventative or therapeutic and gave each company a label based upon those counts. In cases where there is none or a tie between the two word grouping counts, those companies are listed as 'neutral.'

Conclusion

Looking at the last diagram, where the companies are simply sorted by their amount of funding regardless of their base countries, we can see that toward the higher end of the spectrum, we see that there are a greater density of companies focused around preventive care. A possible extension of this study would be to do a similar spread across different years and see if it's changed throughout the years or not.